A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4–7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy

類似資料

• Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome)
  著者:: Pano, Arian, 等
  出版事項: (2015)
• Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS)
  著者:: Muenzer, Joseph, 等
  出版事項: (2017)
• Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future
  著者:: Whiteman, David AH, 等
  出版事項: (2017)
• Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients
  著者:: Giugliani, R., 等
  出版事項: (2017)
• Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)
  著者:: da Silva, Edina MK, 等
  出版事項: (2016)